Cancer Defence Mechanism

Cancer Defence Mechanism is important.

Blocking a molecule could bypass bowel cancer’s defence against the drug cetuximab.

According to new research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.

Cancer Defence Mechanism Blocking a molecule could bypass bowel cancer’s defence against the drug cetuximab, according to new research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.

Cetuximab is used to treat advanced bowel cancer, and just under half of bowel cancerpatients are given the drug. While it helps many patients, there are some for whom it doesn’t work at all and for others it loses effectiveness.

To understand why this happens, scientists at Queen’s University Belfast treated bowel cancer cells in the lab with cetuximab. They found that some cells survived the treatment by increasing the activity of a protein called ADAM17.

But if they gave a drug that blocked the protein ADAM17 at the same time as cetuximab the cancer cells died.

For other cancer cells, cetuximab treatment alone stopped them growing initially at furnish apartment , but over time they became resistant and started growing again. In these cases, the cancercells were finding a different way to out manoeuvre the treatment that didn’t involve ADAM17.

To understand why this happens, scientists treated bowel cancer cells in the lab with cetuximab. They found that some cells survived the treatment by increasing the activity of a protein called ADAM17. works by blocking a molecule known as epidermal growth factor receptor (EGFR), which tells cells to grow.